Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaamanthi, M-
dc.contributor.authorAruna, S-
dc.contributor.authorGirija, R-
dc.contributor.authorVinod, D-
dc.identifier.issn0975-0983(Online); 0376-4699(Print)-
dc.description.abstractA sequence of novel compounds pyrazolopyridine have been prepared by a general synthetic method. Due to high efficiency and selectivity, anticancer agents consisting of combined molecules have gained great interests. The IC50 values have been determined against cell line U937, the results obtained indicate the potential effects against cancer cell line. The cell potency of cell line is best for compounds 4a IC50 = 62.5 μM, 5b IC50 = 62.5 μM,4b IC50 = 31.2 μM, 4e IC50 = 31.2 μM), selectivity and in vivo. Further, the molecular docking studies indicate that substituted pyrazolo[4,3-c]pyridine derivatives show good anticancer activity in the medicinal field. The ease of synthesis and the significant biological activities make these compounds potential new frameworks for progress of cancer therapeutics. Compound 4f shows anticancer effect in cancer cell lines and in vivo that corresponds with antitumor activity in an AML cancer type. For the molecular docking with the ligands, the RMSD value has been calculated, the protein with the least RMSD is found to be 5KTU screening with 20 small molecules.en_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJC-B Vol.60B(05) [May 2021]en_US
dc.subjectMolecular dynamicsen_US
dc.titleDesign, synthesis of novel pyrazolopyridine derivatives and CREBBP bromodomain inhibitors docking and molecular dynamicsen_US
Appears in Collections:IJC-B Vol.60B(05) [May 2021]

Files in This Item:
File Description SizeFormat 
IJCB 60B(5) 746-754.pdfMain Article430.47 kBAdobe PDFView/Open
IJCB 60B(5) 746-754_Suppl Data.pdfSupplementary Data737.03 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.